文献速递慢性肾脏病急性肾损伤

SGLT2抑制剂在慢性肾脏病中的应用:同时预防急性肾损伤的策略?

SGLT2 inhibition in chronic kidney disease: a preventive strategy against acute kidney injury at the same time?
PubMed 文献 · Kidney Int · 2022-01-01

SGLT2抑制剂已知可延缓慢性肾脏病进展,但理论上存在增加急性肾损伤风险的担忧。Heerspink等在DAPA-CKD试验中揭示达格列净降低了肾功能急剧下降的风险,其发现可能让临床医生在给慢性肾脏病患者处方SGLT2抑制剂时更安心。

要点

  • SGLT2抑制剂延缓慢性肾脏病进展,但理论担忧其增加急性肾损伤风险。
  • DAPA-CKD试验中达格列净降低肾功能急剧下降风险。
  • 该发现可能让临床医生对慢性肾脏病患者处方SGLT2抑制剂更安心。

核心结论

  • Heerspink等揭示达格列净在DAPA-CKD试验中降低肾功能急剧下降风险,可能让临床医生对慢性肾脏病患者处方SGLT2抑制剂更安心。

研究设计与样本

  • DAPA-CKD试验(达格列净与慢性肾脏病不良结局预防试验)。

主要发现

  • 达格列净降低了肾功能急剧下降的风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are known to slow down progression of chronic kidney disease. However, theoretical concerns still exist that SGLT2 inhibitors could increase the risk of acute kidney injury. Heerspink et al. revealed that dapagliflozin, an SGLT2 inhibitor, reduced the risk of abrupt declines in kidney function during the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial. Their findings may serve to reassure clinicians prescribing SGLT2 inhibitors to patients with chronic kidney disease.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Hasegawa S, Nangaku M. SGLT2 inhibition in chronic kidney disease: a preventive strategy against acute kidney injury at the same time? Kidney Int. 2022. PMID: 34991813. doi:10.1016/j.kint.2021.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。